Terms: = Kidney tumors AND SETD2, ENSG00000181555, 29072
159 results:
1. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
[TBL] [Abstract] [Full Text] [Related]
2. A novel immune-related lncRNA signature predicts the prognosis and immune landscape in ccRCC.
Dai L; Pan D; Jin J; Lv W
Aging (Albany NY); 2024 Mar; 16(6):5149-5162. PubMed ID: 38484738
[TBL] [Abstract] [Full Text] [Related]
3. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract] [Full Text] [Related]
4. A missense SNP in the tumor suppressor setd2 reduces H3K36me3 and mitotic spindle integrity in Drosophila.
Brockett JS; Manalo T; Zein-Sabatto H; Lee J; Fang J; Chu P; Feng H; Patil D; Davidson P; Ogan K; Master VA; Pattaras JG; Roberts DL; Bergquist SH; Reyna MA; Petros JA; Lerit DA; Arnold RS
Genetics; 2024 Apr; 226(4):. PubMed ID: 38290049
[TBL] [Abstract] [Full Text] [Related]
5. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
[TBL] [Abstract] [Full Text] [Related]
6. Identification of molecular characteristics of FUT8 and alteration of core fucosylation in kidney renal clear cell cancer.
Xin Z; Wen X; Zhou M; Lin H; Liu J
Aging (Albany NY); 2024 Jan; 16(3):2299-2319. PubMed ID: 38277230
[TBL] [Abstract] [Full Text] [Related]
7. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract] [Full Text] [Related]
8. Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis.
Tariki MS; Barberan CCG; Torres JA; Ruano APC; Ferreira Costa DJ; Braun AC; da Silva Alves V; de Cássio Zequi S; da Costa WH; Fay AP; Torrezan G; Carraro DM; Domingos Chinen LT
Pathol Res Pract; 2024 Jan; 253():154918. PubMed ID: 37995423
[TBL] [Abstract] [Full Text] [Related]
9. setd2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
Rao H; Liu C; Wang A; Ma C; Xu Y; Ye T; Su W; Zhou P; Gao WQ; Li L; Ding X
Nat Commun; 2023 Nov; 14(1):7572. PubMed ID: 37989747
[TBL] [Abstract] [Full Text] [Related]
10. Morphological characteristics of setd2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract] [Full Text] [Related]
11. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
[TBL] [Abstract] [Full Text] [Related]
12. setd2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract] [Full Text] [Related]
13. Knockdown of setd2 promotes erastin-induced ferroptosis in ccRCC.
Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
[TBL] [Abstract] [Full Text] [Related]
14. Investigating the Role of
Xu S; Hu X; Chong Y; Zhu G
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569676
[TBL] [Abstract] [Full Text] [Related]
15. A role for setd2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract] [Full Text] [Related]
16. setd2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract] [Full Text] [Related]
17. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
18. setd2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
[TBL] [Abstract] [Full Text] [Related]
19. Targeted Profiling of Epitranscriptomic Reader, Writer, and Eraser Proteins Regulated by H3K36me3.
Yin J; Qi TF; Li L; Wang Y
Anal Chem; 2023 Jun; 95(25):9672-9679. PubMed ID: 37296074
[TBL] [Abstract] [Full Text] [Related]
20. Novel genetically engineered mouse models for clear cell renal cell carcinoma.
van der Mijn JC; Laursen KB; Fu L; Khani F; Dow LE; Nowak DG; Chen Q; Gross SS; Nanus DM; Gudas LJ
Sci Rep; 2023 May; 13(1):8246. PubMed ID: 37217526
[TBL] [Abstract] [Full Text] [Related]
[Next]
